Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

NCT01837251 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

682

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Platinum-sensitive Ovarian Cancer

Interventions

DRUG: Carboplatin
DRUG: PLD
BIOLOGICAL: Bevacizumab

Sponsor

AGO Research GmbH

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]